Overview of Biomarker Testing in NSCLC and Biomarkers Predicting Response to Immune-Based Therapies

Download these slides from a live CCO Webinar for an overview of precision medicine in advanced NSCLC along with the current status of biomarkers guiding optimal use of immunotherapy for the treatment of this disease.
Jamie E. Chaft, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.87 MB
Released: April 14, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Lilly
Regeneron Pharmaceuticals, Inc & Sanofi Genzyme

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Related Content

Download slides reviewing the latest clinical data informing optimal treatment of patients with EGFR-mutant advanced NSCLC, from Clinical Care Options

Edward S. Kim, MD, FACP, FASCO Tetsuya Mitsudomi, MD Luis Paz-Ares, MD, PhD person default Daniel SW Tan, BSc, MBBS, MRCP, PhD Released: June 23, 2021

Download these expert-selected slides covering current recommendations on evaluating and treating patients for NTRK fusion-positive cancer, from Clinical Care Options (CCO).

George D. Demetri, MD Alexander Drilon, MD Theodore Laetsch, MD Released: June 16, 2021

EHR data analysis from ASCO 2021 showed that NGS testing and clinical trial participation were less likely among Black patients with NSCLC than White patients, as reported by Clinical Care Options (CCO)

Released: June 15, 2021

Download these expert-selected slides on slides on treating patients with NTRK-positive tumors with TRK inhibitors, from Clinical Care Options (CCO).

Alexander Drilon, MD Released: June 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue